88 related articles for article (PubMed ID: 9046799)
1. Measurement of cell kinetic parameters in meningiomas.
Nakagawa Y; Sugawa N; Ueda S; Suzuki K; Vignutelli A; Perentes E
Neurol Med Chir (Tokyo); 1997 Jan; 37(1):12-7. PubMed ID: 9046799
[TBL] [Abstract][Full Text] [Related]
2. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry.
Nakaguchi H; Fujimaki T; Matsuno A; Matsuura R; Asai A; Suzuki I; Sasaki T; Kirino T
Cancer; 1999 May; 85(10):2249-54. PubMed ID: 10326705
[TBL] [Abstract][Full Text] [Related]
3. Potential doubling time and tumour doubling time in meningiomas and neurinomas.
Nakasu S; Nakasu Y; Nakajima M; Yokoyama M; Matsuda M; Handa J
Acta Neurochir (Wien); 1996; 138(6):763-70. PubMed ID: 8836295
[TBL] [Abstract][Full Text] [Related]
4. Tumor doubling time as preoperative predictor of malignancy and recurrence in newly diagnosed meningioma.
Miwa Y; Sugawara T; Kobayashi D; Maehara T
Neurosurg Rev; 2022 Dec; 45(6):3683-3687. PubMed ID: 36136254
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 staining index and peritumoral brain edema of meningiomas.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Cancer; 1996 Jul; 78(1):133-43. PubMed ID: 8646709
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
8. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
9. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods.
Nakasu S; Li DH; Okabe H; Nakajima M; Matsuda M
Am J Surg Pathol; 2001 Apr; 25(4):472-8. PubMed ID: 11257621
[TBL] [Abstract][Full Text] [Related]
10. MIB-1 staining index of pediatric meningiomas.
Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
[TBL] [Abstract][Full Text] [Related]
11. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
12. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas.
Matsuno A; Nagashima T; Matsuura R; Tanaka H; Hirakawa M; Murakami M; Tamura A; Kirino T
Am J Clin Pathol; 1996 Dec; 106(6):776-81. PubMed ID: 8980354
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
14. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
16. Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Neurol Med Chir (Tokyo); 1995 May; 35(5):289-93. PubMed ID: 7623949
[TBL] [Abstract][Full Text] [Related]
17. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
18. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
19. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]